Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.83 HKD | +0.74% | -2.15% | +2.25% |
Apr. 15 | Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug | MT |
Apr. 15 | Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China | CI |
Sales 2024 * | 437M 60.36M 472M | Sales 2025 * | 800M 111M 864M | Capitalization | 4.39B 606M 4.74B |
---|---|---|---|---|---|
Net income 2024 * | -251M -34.66M -271M | Net income 2025 * | -3M -414K -3.24M | EV / Sales 2024 * | 8.29 x |
Net cash position 2024 * | 762M 105M 823M | Net cash position 2025 * | 706M 97.48M 762M | EV / Sales 2025 * | 4.6 x |
P/E ratio 2024 * |
-17.6
x | P/E ratio 2025 * |
-84.3
x | Employees | 444 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 47.42% |
1 day | +0.74% | ||
1 week | -2.15% | ||
Current month | +0.74% | ||
1 month | -8.32% | ||
3 months | +33.66% | ||
6 months | -0.58% | ||
Current year | +2.25% |
Managers | Title | Age | Since |
---|---|---|---|
Ye Liu
CEO | Chief Executive Officer | 53 | 18-07-31 |
Tim Ruan
DFI | Director of Finance/CFO | 38 | 23-01-11 |
Dong Hong Chen
CTO | Chief Tech/Sci/R&D Officer | 53 | 19-10-27 |
Members of the board | Title | Age | Since |
---|---|---|---|
Wei Li
BRD | Director/Board Member | 52 | 18-03-31 |
Yan Ling Cao
BRD | Director/Board Member | 39 | 19-06-17 |
Ting Yuk Wu
BRD | Director/Board Member | 69 | 20-06-22 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.59% | 4 M€ | -27.92% | ||
0.00% | 34 M€ | +4.01% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-03 | 6.83 | +0.74% | 945 600 |
24-05-31 | 6.78 | +0.59% | 1,170,500 |
24-05-30 | 6.74 | +1.35% | 321,500 |
24-05-29 | 6.65 | -1.63% | 591,500 |
24-05-28 | 6.76 | -0.59% | 867,000 |
Delayed Quote Hong Kong S.E., June 03, 2024 at 04:08 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.25% | 601M | |
+42.60% | 739B | |
+32.34% | 598B | |
-5.74% | 353B | |
+17.79% | 318B | |
+3.40% | 285B | |
+16.47% | 240B | |
+9.26% | 210B | |
-5.07% | 206B | |
+6.74% | 164B |
- Stock Market
- Equities
- 1477 Stock